NCT06614036View on ClinicalTrials.gov

Remimazolam Versus Midazolam for Sedation During Upper GI Endoscopy: a Randomized Controlled Trial

PHASE4RecruitingINTERVENTIONAL

Enrollment

148

Participants

Timeline

Start Date

October 21, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

April 30, 2026

Conditions

Sedation for Diagnostic Gastroscopy

Interventions

DRUG

Remimazolam

Byfavo 20 mg powder for solution for injection, remimazolam. Each vial contains remimazolam besylate equivalent to 20 mg remimazolam. Concentration after reconstitution: 2.5 mg/ml.

DRUG

Midazolam

Midazolam 1mg/ml, solution for injection / infusion. Each 5ml ampoule contains 5mg midazolam. Concentration: 1mg/ml.

Trial Locations (3)

7334DZ

RECRUITING

Gelre Hospitals, Apeldoorn

6815AD

RECRUITING

Rijnstate hospital, Arnhem

3435CM

RECRUITING

St Antonius hospital, Nieuwegein

All Listed Sponsors

collaborator

Gelre Hospitals

OTHER

collaborator

Rijnstate Hospital

OTHER

lead

Koen Munters

OTHER

NCT06614036 - Remimazolam Versus Midazolam for Sedation During Upper GI Endoscopy: a Randomized Controlled Trial | Biotech Hunter | Biotech Hunter